Click image to enlarge
The
V-PLEX platform offers analytically validated singleplex and multiplex assay kits. Developed under rigorous design control, V-PLEX kits provide accurate and reproducible results with consistency from lot to lot. The V-PLEX Plus Metabolic Panel 1 (NHP) Kit includes six biomarkers that are associated with metabolic diseases (Table 1). The assays can be used for quantitative measurements in the sample types listed in the “Specifications” tab below and offer low detection limits (LLODs and LLOQs).
V-PLEX Plus kits include controls, wash buffer, and plate seals.
| Analyte | LLOD | LLOQ | ULOQ | Dynamic Range | Unit | | C-Peptide | 4.72 | 19 | 3,150 | 4.72 - 3,150 | pg/mL |
| GIP (active) | 0.233 | 3.18 | 390 | 0.233 - 390 | pg/mL |
| GLP-1 (active) | 0.011 | 0.1 | 39 | 0.011 - 39 | pM |
| Glucagon | 0.015 | 0.33 | 52 | 0.015 - 52 | pM |
| Insulin | 0.006 | 0.07 | 19.5 | 0.006 - 19.5
| μIU/mL |
| PP | 0.043 | 0.41 | 325 | 0.043 - 325 | pg/mL |
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Application(s)
|
|
Metabolic
|
|
|
Analyte(s)
|
|
C-Peptide, GIP (active), GLP-1 (active), Glucagon, Insulin, PP
|
|
|
Species
|
|
Non-human primate
|
|
|
Instrument(s)
|
|
SECTOR Imager 6000
,
MESO QuickPlex SQ 120
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
MESO SECTOR S 600MM
|
|
|
Plate Type
|
|
96-well
|
|
|
Sample Type
|
|
Cell Culture Supernatant, P800 Plasma, Serum
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Metabolic Panel 1 Control 1
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
Metabolic Panel 1 Control 2
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
Metabolic Panel 1 Control 3
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
Metabolic Panel 1 (human) SECTOR Plate
|
2-8 °C
|
1 each
(1 plate)
|
|
|
|
Diluent Assembly 25 (includes Diluent 56 – 10 mL, and Diluent 11 – 5 mL)
|
≤-10 °C
|
1 each
(1 each)
|
|
|
|
|
RT
|
1 bottle
(18 mL)
|
|
|
|
|
RT
|
1 bottle
(100 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Metabolic Panel 1 Control 1
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
Metabolic Panel 1 Control 2
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
Metabolic Panel 1 Control 3
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
Metabolic Panel 1 (human) SECTOR Plate
|
2-8 °C
|
5 each
(1 plate)
|
|
|
|
Diluent Assembly 26 (includes Diluent 56 – 50 mL, and Diluent 11 – 50 mL)
|
≤-10 °C
|
1 each
(1 each)
|
|
|
|
|
RT
|
1 bottle
(90 mL)
|
|
|
|
|
RT
|
1 bottle
(100 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Metabolic Panel 1 Control 1
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
Metabolic Panel 1 Control 2
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
Metabolic Panel 1 Control 3
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
Metabolic Panel 1 (human) SECTOR Plate
|
2-8 °C
|
25 each
(1 plate)
|
|
|
|
Diluent Assembly 26 (includes Diluent 56 – 50 mL, and Diluent 11 – 50 mL)
|
≤-10 °C
|
5 each
(1 each)
|
|
|
|
|
RT
|
5 bottle
(90 mL)
|
|
|
|
|
RT
|
5 bottle
(100 mL)
|
|
|
|
Product Inserts
|
|
|
|
Certificate of analysis
|
|
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops
|
|
|
|
Leptin levels are associated with multiple sclerosis risk
|
|
|
|
Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice.
|
|
|
|
Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats
|
|
|
|
Enrichment of human embryonic stem cell-derived NKX6.1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo.
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters